I love the partnerships, the team, and the ideal timing of just after the avian flu/egg pandemic. I do have a few questions though. 1) Why does ASFV has three separate treatments versus one for other viruses? 2) Can you clarify what level of testing you've done for your most a...

Hi Jason, Thank you for your interest. I'm pleased to address your questions: 1. Efficacy Validation ASFV is a complex virus with over 150 genes and multiple immune evasion mechanisms, including T-cell inhibition, B-cell/antibody evasion, and macrophage toxicity. Our vaccine approach directly addresses these adaptations in relation to the viral replication cycle to prevent early infection establishment. Blocking these escape routes is critical to achieving high and lasting efficacy. 2. Regula...

1. Efficacy validationCan you share the third-party or peer-reviewed data behind the “~100% efficacy” claim for your SVA/ASFV models? 2) What is your planned sequence with the USDA Center for Veterinary Biologics (or other regulators) for bringing these vaccines to market, and...

Hi Sorin, Thank you for your thoughtful questions. 1) Our vaccines that are approaching ~100% protection include SVA and SIV, as we have seen in our unpublished and confidential early challenge models. However, we have multiple peer-reviewed publications building up to the early challenge studies that can be easily found on PubMed by searching 'Diego Diel SVA and SIV'. We have yet to test the ASFV vaccines in challenge studies and do not hold this claim at this time. 2) We are pursuing the US...

Kermode Biotechnologies

AI-Powered Immunity: Protecting Farms from Viral Threats

kermodebio.com

Denver, CO

Notable Angel Biotech

What Investors Say

LEAD INVESTOR

Invested $50,000 this round + $300,000 previously

As lead investor, I believe Kermode Biotechnologies is tackling one of the most pressing threats to global food security: African Swine Fever (ASF). ASF has devastated the pork industry, causing massive losses and billions in global economic damage. Despite this, no fully effective solution has reached the market—until now. Kermode offers a scientifically superior approach to ASF prevention and has recently partnered with Cornell University, a global leader in animal health research. This alliance significantly strengthens its technical capabilities. The company has also advanced two clinical-trial-ready products, creating near-term commercial opportunities. Backed by an exceptional management team with expertise in virology, animal health, and biotech commercialization, Kermode represents a unique chance to reshape livestock health and address a $20+ billion unmet market need. I’m proud to support this team and mission.

What People Say

Kermode Biotechnologies

Quick facts

Team profiles

Featured investor profiles

$77,211

What Investors Say